Jazz Pharmaceuticals plc (JAZZ)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 1,045,712 | 897,841 | 1,054,969 | 1,023,825 |
| Selling, general and administrative | 358,399 | 514,013 | 325,772 | 338,523 |
| Research and development | 189,972 | 180,652 | 199,919 | 220,734 |
| Acquired in-process research and development | 905,362 | - | - | - |
| Intangible asset amortization | 162,103 | 154,448 | 157,457 | 155,223 |
| Cost of product sales (excluding amortization of acquired developed technologies) | 116,268 | 104,620 | 111,611 | 109,902 |
| Total operating expenses | 1,732,104 | 953,733 | 794,759 | 824,382 |
| Income (loss) from operations | -686,392 | -55,892 | 260,210 | 199,443 |
| Interest expense, net | -47,363 | -53,706 | -58,702 | -62,023 |
| Foreign exchange gain (loss) | -1,799 | -213 | -701 | 507 |
| Income (loss) before income tax benefit and equity in loss of investees | -735,554 | -109,811 | 200,807 | 137,927 |
| Equity in loss of investees | -86 | -542 | -285 | -12 |
| Income tax benefit | -17,170 | -17,812 | -14,533 | -30,653 |
| Net income (loss) | -718,470 | -92,541 | 215,055 | 168,568 |
| Basic (in dollars per share) | -11.74 | -1.52 | 3.5 | 2.68 |
| Diluted (in dollars per share) | -11.74 | -1.52 | 3.42 | 2.49 |
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | 61,194,000 | 60,979,000 | 61,414,000 | 62,882,000 |
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) | 61,194,000 | 60,979,000 | 63,174,000 | 69,625,000 |